<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>963</ReferenceId>
        <DateLastUpdated>2016-11-03-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11531418</PubmedId>
            <Abstract>We prepared recombinant Japanese encephalitis (JE) virus populations possessing random mutations at the envelope (E) protein region by a long PCR-based method. Neutralization-resistant mutants were selected from these populations by application of JE-specific virus neutralizing monoclonal antibody (mAb) 503, which possessed a 51,200-fold neutralization titer. We classified the mutants into three groups, each bearing two amino acid alterations at the E protein region: 52, Gln-Arg, and 136, Lys-Glu; 136, Lys-Glu, and 275, Ser-Pro; and 126, Ile-Thr, and 136, Lys-Glu, respectively. Three different genetically engineered variants, each bearing a single mutation, 126, Ile-Thr; 136, Lys-Glu; and 275, Ser-Pro, respectively, showed partial but not complete recovery of reactivity to mAb 503. Our results indicate that the amino acid substitutions at amino acid positions 52, 126, 136, and 275 altered the structure of the neutralization epitope for mAb 503 on the E protein. All these mutations were clustered at the junction of domains I and II of the E protein and it is likely that the epitope for mAb 503 is composed of at least E(0)-e, D(0)-a, and k strands of the E protein. We also demonstrated the efficacy of the long PCR-based recombinant virus technique as a useful tool for the creation of a variety of mutants bearing random mutations at targeted areas of the virus genome.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>417-26</ArticlePages>
            <ArticleTitle>Locus of a virus neutralization epitope on the Japanese encephalitis virus envelope protein determined by use of long PCR-based region-specific random mutagenesis.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Morita</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Tadano</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Nakaji</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Kosai</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Mathenge</LastName>
                    <ForeName>E G</ForeName>
                </Author>
                <Author>
                    <LastName>Pandey</LastName>
                    <ForeName>B D</ForeName>
                </Author>
                <Author>
                    <LastName>Hasebe</LastName>
                    <ForeName>F</ForeName>
                </Author>
                <Author>
                    <LastName>Inoue</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Igarashi</LastName>
                    <ForeName>A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Virology, Institute of Tropical Medicine, Nagasaki University, Sakamoto-machi 1-12-4, Nagasaki City, 852-8523, Japan. moritak@net.nagasaki-u.ac.jp</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Epitopes;Membrane Glycoproteins;Recombinant Proteins;Viral Envelope Proteins;glycoprotein E, Japanese encephalitis virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(immunology); Antibody Affinity; Cells, Cultured; Encephalitis Virus, Japanese(genetics; immunology); Epitopes(immunology); Membrane Glycoproteins(genetics; immunology); Mice; Mutagenesis; Neutralization Tests; Polymerase Chain Reaction; Recombinant Proteins(immunology); Recombination, Genetic; Viral Envelope Proteins(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>287</Volume>
                <Issue>2</Issue>
                <Title>Virology</Title>
                <Issn>0042-6822</Issn>
                <MedlineTa>Virology</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>mAB503 epitope</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>Q52, I126, K136, S275</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAK31640.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000445</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Absract</LocationOfData>
                <EpitopeId>76982</EpitopeId>
                <ReferenceRegion>Q52, I126, K136, S275</ReferenceRegion>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>Generated mAB503-escape mutants from region-specific random mutagenesis of E protein coding sequence and produced mAb503-escape mutants from wild-type virus to determine epitopic determinants.  Single mutations retained mAb binding activity, while three double-mutants at positions 136 and 275; 126, 136; and 52 and 136 resulted in complete loss of mAbg binding.  Naturally occuring viral escape mutant suggests position 52 is a critical residue.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>11750</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 wo</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000446</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV JaGAr-01 live virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>Mice were primed with 400 PFU i.v. followed by two i.p injections boosts of 8000 HA units JEV virus at 9 and 14 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were sacrificed three days after final innoculation and splenocytes harvested for fusion to NS-1 myeloma cells; mAb 503 is JEV-specific Ab.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Antigen capture ELISA was performed on several mAb503-escape mutants from region-specific random mutagenesis and on escape mutants from wild-type virus. Wild-type was used as a postive control. Polyclonal anti-JE Ab was used to detect antigen capture.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb503</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Japanese Encephalitis virus (JEV)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000445</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>11753</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 wo</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000446</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV JaGAr-01 live virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>Mice were primed with 400 PFU i.v. followed by two i.p injections boosts of 8000 HA units JEV virus at 9 and 14 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were sacrificed three days after final innoculation and splenocytes harvested for fusion to NS-1 myeloma cells; mAb301 was one of several monoclonals produced and has been shown to be flavivirus cross-reactive (Dengue virus type 2, West Nile Virus, JEV)</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Antigen capture ELISA was performed on several mAb503-escape mutants from region-specific random mutagenesis and on escape mutants from wild-type virus.  Wild-type was used as a postive control. Polyclonal anti-JE Ab was used to detect antigen capture.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb301 (flavivirus cross-reactive)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Japanese Encephalitis virus (JEV)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000445</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>11751</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 wo</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000446</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV JaGAr-01 live virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>Mice were primed with 400 PFU i.v. followed by two i.p injections boosts of 8000 HA units JEV virus at 9 and 14 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were sacrificed three days after final innoculation and splenocytes harvested for fusion to NS-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Neutralization was measured using a focus reduction assay. Neutralization end-point was tire agaisnt mAb503 as determined at 50% reduction in focus-forming units in infected BHK cells. NT assay was performed on several mAb503-escape mutants from region-specific random mutagenesis and on escape mutants from wild-type virus. Wild-type was used as a postive control with a NT endopoint of 51,200X.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb503</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Japanese Encephalitis virus (JEV)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000445</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

